Triple Negative Breast Cancer
Breast cancer can be characterized a number of different ways: ER-positive for tumors driven by Estrogen Receptors, PR-positive for tumors driven by Progesterone Receptors or HER2-positive for tumors driven by HER2-neu gene receptors. A patient that is positive for any of these three markers has targeted therapies available to them. Tumors that are not positive for any of these three known receptors fall into a fourth category, known as triple negative breast cancer (TNBC).
In many ways, TNBC is the last frontier in breast cancer, as there are currently no targeted therapeutics available for this population. Treatment options that are currently under development for TNBC face significant challenges and have been met with mixed results in clinical trials. Diagnostic options are extremely limited, and TNBC-specific directed therapeutic options do not yet exist.
Insight Genetics aims to shine a light on TNBC and lead the way in developing meaningful diagnostics that open up a new realm of information and therapies for TNBC patients and their treatment teams.
Insight Genetics’ proprietary Insight TNBCtype™ is the first and only CLIA-validated assay for TNBC molecular subtyping. It can enable prospective clinical trials and advance targeted therapies for TNBC patients.
We have partnered with Dr. Jennifer Pietenpol and her laboratory at Vanderbilt University, whose seminal work on TNBC subtyping is changing the way the disease is approached.
Click here for Clinical Evidence
Click here for the Insight TNBCtype Requisition Form